Result of an open-label phase 2 trial of dual TORC1/TORC2 inhibitor onatasertib (ATG-008) in HBV+ advanced hepatocellular carcinoma (HCC) subjects who have received at least one prior line of systemic therapy (TORCH)

被引：0

|

作者：

Qin, Shukui

Lin, Xiaoyan

Meng, Zhiqaing

Ren, Zhenggang

Bai, Yuxian

Gu, Shanzhi

Zheng, Li

Li, Qiu

Oh, Sun-Yong

Guo, Yabing

Kang, Yoong-Koo

Kao, Wei-Yu

Li, Wei

Yoon, Jung-Hwan

Zhang, Helong

Chen, Pei-Jer

Yang, Tsai-Sheng

Heo, Jeong

Zheng, Zhendong

Xie, Hui

Yu, Zhinuan

机构：

来源：

CANCER RESEARCH | 2023年 / 83卷 / 08期

关键词：

D O I：

10.1158/1538-7445.AM2023-CT150

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT150

引用

收藏

页数：3

相关论文

共 2 条

[1] TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor
Choueiri, Toni K.
Albiges, Laurence
Mckay, Rana R.
Pal, Sumanta K.
Hammers, Hans J.
Heng, Daniel Yick Chin
Beckermann, Katy
Kasturi, Vijay
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[2] TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor.
Choueiri, Toni K.
Albiges, Laurence
Hammers, Hans J.
Mckay, Rana R.
Heng, Daniel Yick Chin
Beckermann, Katy
Kasturi, Vijay
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)